These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28719114)

  • 1. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: © NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
    BJU Int; 2017 Aug; 120(2):168-184. PubMed ID: 28719114
    [No Abstract]   [Full Text] [Related]  

  • 2. NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancer.
    Elsada A; Pearce F; George E; Adler A
    Lancet Oncol; 2014 Sep; 15(10):1058-9. PubMed ID: 25328938
    [No Abstract]   [Full Text] [Related]  

  • 3. [Enzalutamide-new option in metastatic castration-sensitive prostate cancer? : Preliminary results of a randomized phase III trial (ENZAMET)].
    Boegemann M
    Urologe A; 2020 Jan; 59(1):78-79. PubMed ID: 31853892
    [No Abstract]   [Full Text] [Related]  

  • 4. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
    Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
    Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving role of enzalutamide on the treatment of prostate cancer.
    Nadal R; Bellmunt J
    Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer.
    Sanford M
    Drugs; 2013 Oct; 73(15):1723-32. PubMed ID: 24127223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide.
    Baciarello G; Sternberg CN
    Crit Rev Oncol Hematol; 2016 Oct; 106():14-24. PubMed ID: 27637350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.
    Graff JN; Gordon MJ; Beer TM
    Expert Opin Pharmacother; 2015 Apr; 16(5):749-54. PubMed ID: 25687355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
    Albiges L; Loriot Y; Massard C; Fizazi K
    Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
    Graff JN; Baciarello G; Armstrong AJ; Higano CS; Iversen P; Flaig TW; Forer D; Parli T; Phung D; Tombal B; Beer TM; Sternberg CN
    Ann Oncol; 2016 Feb; 27(2):286-94. PubMed ID: 26578735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased survival with enzalutamide in prostate cancer after chemotherapy.
    Scher HI; Fizazi K; Saad F; Taplin ME; Sternberg CN; Miller K; de Wit R; Mulders P; Chi KN; Shore ND; Armstrong AJ; Flaig TW; Fléchon A; Mainwaring P; Fleming M; Hainsworth JD; Hirmand M; Selby B; Seely L; de Bono JS;
    N Engl J Med; 2012 Sep; 367(13):1187-97. PubMed ID: 22894553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical guide to the use of enzalutamide.
    Hoffman-Censits J; Kelly WK
    Can J Urol; 2014 Apr; 21(2 Supp 1):64-9. PubMed ID: 24775726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
    Davis ID; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx G; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Sweeney CJ;
    N Engl J Med; 2019 Jul; 381(2):121-131. PubMed ID: 31157964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials.
    Shelan M; Achard V; Appiagyei F; Mose L; Zilli T; Fankhauser CD; Zamboglou C; Mohamad O; Aebersold DM; Cathomas R
    Prostate Cancer Prostatic Dis; 2024 Sep; 27(3):422-431. PubMed ID: 38589645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzalutamide: A Review in Castration-Resistant Prostate Cancer.
    Scott LJ
    Drugs; 2018 Dec; 78(18):1913-1924. PubMed ID: 30535926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prostate cancer - enzalutamide extends survival].
    Aktuelle Urol; 2014 Mar; 45(2):98. PubMed ID: 24818263
    [No Abstract]   [Full Text] [Related]  

  • 17. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
    Maeda H; Saito A
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Beer TM; Armstrong AJ; Rathkopf DE; Loriot Y; Sternberg CN; Higano CS; Iversen P; Bhattacharya S; Carles J; Chowdhury S; Davis ID; de Bono JS; Evans CP; Fizazi K; Joshua AM; Kim CS; Kimura G; Mainwaring P; Mansbach H; Miller K; Noonberg SB; Perabo F; Phung D; Saad F; Scher HI; Taplin ME; Venner PM; Tombal B;
    N Engl J Med; 2014 Jul; 371(5):424-33. PubMed ID: 24881730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.
    Sternberg CN; de Bono JS; Chi KN; Fizazi K; Mulders P; Cerbone L; Hirmand M; Forer D; Scher HI
    Ann Oncol; 2014 Feb; 25(2):429-34. PubMed ID: 24478320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.
    Keating GM
    Drugs Aging; 2015 Mar; 32(3):243-9. PubMed ID: 25711765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.